Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Current Deferred Revenue (2016 - 2025)

Adma Biologics' Current Deferred Revenue history spans 11 years, with the latest figure at $143000.0 for Q2 2025.

  • For Q2 2025, Current Deferred Revenue fell 87.35% year-over-year to $143000.0; the TTM value through Jun 2025 reached $143000.0, down 87.35%, while the annual FY2024 figure was $143000.0, 21.43% down from the prior year.
  • Current Deferred Revenue reached $143000.0 in Q2 2025 per ADMA's latest filing, roughly flat from $143000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $1.1 million in Q2 2024 to a low of $142834.0 in Q1 2021.
  • Average Current Deferred Revenue over 5 years is $254074.4, with a median of $142834.0 recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: soared 691.13% in 2024, then crashed 87.35% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $142834.0 in 2021, then rose by 0.12% to $143000.0 in 2022, then increased by 27.27% to $182000.0 in 2023, then decreased by 21.43% to $143000.0 in 2024, then changed by 0.0% to $143000.0 in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Current Deferred Revenue are $143000.0 (Q2 2025), $143000.0 (Q1 2025), and $143000.0 (Q4 2024).